$2.56
-0.06 (-2.29%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where FATE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
22 interventional · 2 observational · 3 with posted results
Held by 15 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, JANE STREET GROUP, LLC, +10 more) · FINRA short interest 4.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus NephritisNCT07570862Complete Renal Response (CRR) at Week 26Open-label · Treatment | Phase 2 | Recruiting | Biological: FT819 | Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | 53 | 2029-07-01 | in 1,047 d | 2026-08-17 |
| FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid TumorsNCT06241456Number of participants with dose limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: FT825, Fludarabine, Cyclophosphamide, Bendamustine, Docetaxel, Cisplatin, Cetuximab | Advanced Solid Tumor | 351 | 2029-05-01 | in 986 d | 2025-12-09 |
| FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsNCT07216105Number of participants with dose limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: FT836, Paclitaxel, Cetuximab, Trastuzumab | Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma | 113 | Jan 2028 | ≤ 530 d | 2026-04-07 |
| A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseaseNCT06308978Number of participants with treatment-emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: FT819, Fludarabine, Cyclophosphamide, Bendamustine | Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis | 244 | 2027-09-30 | in 407 d | 2026-05-22 |
| FT819 in Subjects With B-cell MalignanciesNCT04629729Incidence and nature of dose-limiting toxicities within each dose level cohortNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: FT819, Cyclophosphamide, Fludarabine, IL-2, Bendamustine | Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia | 54 | 2025-06-18actual | — | 2026-03-19 |
| FT596 in Combination With R-CHOP in Subjects With B-Cell LymphomaNCT05934097Incidence of dose-limiting toxicities within each dose escalation cohortNon-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: This study was withdrawn (Sponsor decision). | Drug: FT596, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab, Bendamustine | Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma | 0 | May 2026 | — | 2023-07-06 |
| FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)NCT05950334Number of participants with dose limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: FT522, Rituximab, Cyclophosphamide, Fludarabine, Bendamustine | Relapsed/Refractory B-Cell Lymphoma | 20 | 2025-06-06actual | — | 2025-08-22 |
| FT576 in Subjects With Multiple MyelomaNCT05182073Incidence and nature of DLTs within each dose-escalation cohort to determine the MTD or MADNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine, Daratumumab, Bendamustine | Multiple Myeloma, Myeloma | 31 | 2024-09-20actual | — | 2025-12-12 |
| FT516 in Subjects With Advanced Hematologic MalignanciesNCT04023071The incidence of subjects with Dose Limiting Toxicities within each dose level cohort.Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was terminated by the Sponsor. | Drug: FT516, Rituximab, Obinutuzumab, Cyclophosphamide, Fludarabine, IL-2, Bendamustine | Acute Myelogenous Leukemia, B-cell Lymphoma | 72 | 2023-10-23actual | — | 2023-10-26 |
| FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesNCT04245722Incidence of dose-limiting toxicities within each dose level cohortNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was terminated by the Sponsor. | Drug: FT596, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab, Bendamustine | Lymphoma, B-Cell, Chronic Lymphocytic Leukemia | 98 | 2023-09-27actual | — | 2023-10-26 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyNCT04106167observationalOverall Survival (OS) post-Infusion | — | Terminatedsponsor's stated reason: This study was terminated by the Sponsor. | Genetic: Allogeneic natural killer (NK) cell | Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma | 20 | 2023-08-11actual | — | 2023-09-21 |
| FT516 in Combination With Monoclonal Antibodies in Advanced Solid TumorsNCT04551885Incidence of Dose-Limiting Toxicities (DLTs) Within Each Dose Level CohortOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: This study was terminated by the Sponsor. | Drug: FT516, Avelumab, Cyclophosphamide, Fludarabine, IL-2 | Solid Tumor, Adult | 12 | 2023-08-11actual | — | 2023-09-21 |
| FT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsNCT05069935Define the Recommended Phase 2 Dose (RP2D)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: This study was terminated by the Sponsor. | Drug: FT538, Cyclophosphamide, Fludarabine · Combination product: Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion | Solid Tumor, Adult | 16 | 2023-08-11actual | — | 2023-09-21 |
| FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsNCT05395052Determine the Recommended Phase 2 Dose (RP2D)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: This study was terminated by the Sponsor. | Drug: FT536, Cyclophosphamide, Fludarabine, IL-2, IL-2 · Combination product: Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab | Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer | 5 | 2023-08-11actual | — | 2023-09-21 |
| FT538 in Subjects With Advanced Hematologic MalignanciesNCT04614636Incidence of dose-limiting toxicities (DLTs) within each dose level cohortNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: This study was terminated by the Sponsor. | Drug: FT538, Cyclophosphamide, Fludarabine, Daratumumab, Elotuzumab | Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma | 42 | 2023-07-13actual | — | 2023-09-21 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsNCT03841110The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2 | Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma | 37 | 2022-11-15actual | — | 2023-05-01 |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic MalignanciesNCT02743351results2023-02-08Percentage of Participants With Cumulative Incidence of Grade II to IV aGvHD Through Day +100 Based on Investigator AssessmentRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 1/2 | Completed | Biological: ProTmune, Control Arm | Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease | 96 | 2020-12-04actual | — | 2023-02-08 |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid TumorsNCT03319459Incidence of dose-limiting toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: FATE-NK100, Cetuximab, Trastuzumab | HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor, Advanced Solid Tumors, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreatic Cancer, Melanoma | 44 | 2020-05-29actual | — | 2021-11-22 |
| Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular ImmunotherapyNCT04093622observationalOverall Survival (OS) post-infusion | — | Terminatedsponsor's stated reason: Incorporation of LTFU into the main interventional study. | Genetic: Genetically engineered NK cells | Hematological Malignancy | 2 | 2020-04-09actual | — | 2022-08-29 |
| A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic MalignanciesNCT02354417results2018-10-10Safety Profile, Primarily Assessed by Neutrophil EngraftmentOpen-label · Treatment | Phase 1 | Terminated | Biological: Biological: ProHema-CB | Hematologic Malignancies | 3 | Dec 2016actual | — | 2018-10-10 |
| A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic DisordersNCT02354443results2018-10-10Safety Profile, Assessed Primarily by Neutrophil EngraftmentOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business decision | Biological: ProHema-CB Transplant | Metabolic Disorders | 1 | Dec 2016actual | — | 2018-10-10 |
| The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.NCT01627314Rate of early neutrophil engraftment using Myeloablative ConditioningRandomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Business decision | Biological: ProHema-CB, Untreated CB | Hematologic Malignancies | 62 | Mar 2016actual | — | 2021-11-30 |
| Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood UnitNCT01527838Neutrophil engraftment/chimerismOpen-label · Treatment | Phase 1 | Completed | Biological: Single FT1050 treated UCB unit | Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease, Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | 10 | Oct 2013actual | — | 2016-09-12 |
| Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.NCT00890500Determine the safety of ProHema modulated umbilical cord blood units when used for transplantation in a reduced intensity, sequential umbilical cord blood transplantation model.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Fludarabine, Melphalan, Antithymocyte Globulin, Sirolimus, Tacrolimus | Hematologic Malignancies, Allogeneic Stem Cell Transplantation | 12 | May 2013actual | — | 2013-10-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19